Answers are grounded in this paper and cite their sources.
Randomized trial demonstrates comparable lesion reduction between Chlorin e6 photodynamic therapy and doxycycline in moderate-to-severe rosacea, indicating a durable alternative.
• The chlorophyll-based dihydroporphyrin derivative is a photosensitizer with several advantages, including the absence of a requirement for intracellular transformation, a faster metabolic rate, and notable antibacterial effects. • Chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) effectively reduces papulopustular lesion counts, alleviates erythema, and mitigates subjective symptoms such as pruritus and burning. Its therapeutic efficacy is comparable to that of doxycycline, offering a viable alternative for managing rosacea. • STBF-PDT demonstrated a lower relapse rate and achieved a significantly greater reduction in Demodex mite counts compared to oral doxycycline. • The adverse reactions associated with STBF-PDT, including transient acute inflammation and pain, are mild and short-lived. Photodynamic therapy (PDT) is beneficial for managing rosacea, and chlorin e6 derivative-mediated photodynamic therapy (STBF-PDT) has demonstrated efficacy in reducing acne lesions with mild adverse reactions. This study aimed to assess the effectiveness and safety of STBF-PDT for the treatment of moderate-to-severe rosacea. In this prospective, randomised, evaluator-blind controlled study, patients with moderate-to-severe rosacea were assigned to receive up to six STBF-PDT sessions or 100 mg of doxycycline daily for eight weeks, followed by a 24-week follow-up. A total of 76 patients were enrolled (38 assigned to STBF-PDT and 38 to oral doxycycline) with 69 (36 in the STBF-PDT group and 33 in the doxycycline group) completing the study. At the end of treatment, the median reduction in lesion count was 82.3% in the STBF-PDT group and 81.8% in the doxycycline group, indicating no significant difference between the groups. The STBF-PDT group exhibited a lower relapse rate and a significantly higher reduction in Demodex mites. Clinician's Erythema Assessment success (CEA), sensations of burning and pruritus, telangiectasia, and Rosacea-related Quality of Life (RosaQoL) scores were comparable between groups. No severe adverse reactions were observed. STBF-PDT is a promising treatment option for mild-to-moderate rosacea with mild adverse reactions.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: